DESCRIPTION (provided by applicant): Caffeine has widespread effects in the 90 percent of US adults who consume it daily. Recent research in our laboratory indicates that caffeine has disruptive effects on glucose metabolism that may seriously impair glycemic control in type 2 diabetes and aggravate insulin resistance in pre-diabetic individuals. We propose 4 studies to determine the nature and extent of caffeine's effects and their potential importance to diabetes. A replication and extension of our preliminary study will examine the effects of a controlled dose of caffeine on fasting glucose and insulin and responses to the oral glucose tolerance test (OGTT) to determine whether caffeine aggravates hyperglycemic and hyperinsulinemic responses in type 2 diabetes patients. We will test a variety of clinical and physiological factors that could account for individual differences in caffeine's effects, to identify patients at greatest risk of impairment and to elucidate potential mechanisms of action.
A similar study will determine caffeine's effects on glucose metabolism in subjects who are currently "pre-diabetic," but at risk of developing clinical diabetes. Confirming that caffeine increases insulin resistance and may elicit hyperglycemia in this group would establish caffeine as a factor that could aggravate and contribute to the metabolic processes that lead to the development of diabetes in this high-risk group.
A third study will extend our laboratory findings into the natural environment and explore the use of continuous glucose monitoring system (CGMS) methodologies to determine the effects of caffeine consumption on blood glucose during normal daily activities. These ambulatory measurements will complement the controlled laboratory studies and establish the ecological importance of these effects.
Together these studies will establish a foundation of evidence regarding caffeine's effects on glucose metabolism and their importance to clinical glucose management in type 2 diabetes. This foundation will support later studies of mechanism as well as clinical intervention trials.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
044387793
UEI
TP7EK8DZV6N5
Project Start Date
01-July-2004
Project End Date
31-December-2007
Budget Start Date
01-June-2006
Budget End Date
31-December-2007
Project Funding Information for 2006
Total Funding
$353,396
Direct Costs
$229,478
Indirect Costs
$123,918
Year
Funding IC
FY Total Cost by IC
2006
National Institute of Diabetes and Digestive and Kidney Diseases
$353,396
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DK067486-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DK067486-03
Patents
No Patents information available for 5R01DK067486-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DK067486-03
Clinical Studies
No Clinical Studies information available for 5R01DK067486-03
News and More
Related News Releases
No news release information available for 5R01DK067486-03
History
No Historical information available for 5R01DK067486-03
Similar Projects
No Similar Projects information available for 5R01DK067486-03